XML 40 R42.htm IDEA: XBRL DOCUMENT v3.20.1
Acquisitions (Details 2) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 31, 2020
 [1],[2]
Mar. 31, 2019
Mar. 31, 2020
 [3]
Mar. 31, 2019
Business Combinations [Abstract]        
Total revenues, net $ 10,331,629 $ 10,575,866 $ 34,276,368 $ 36,916,501
Net income (loss) $ (5,850,703) $ (8,740,850) $ (18,197,902) $ (17,205,490)
Net income (loss) per share [4] $ (0.17) $ (0.39) $ (0.80) $ (0.76)
[1] Due to the absence of discrete financial information for Innovus, covering the period from February 1, 2020 through February 13, 2020, the Company did not include the impact of that stub-period for the pro forma results for the three and nine months ended March 31, 2020.
[2] For the three months ended March 31, 2020, Pediatric Portfolio acquisition occurred prior to the three months ended March 31, 2020, and accordingly, the results of the Pediatric Portfolio are fully consolidated into the Company's results for the three months ended March 31, 2020.
[3] Due to a lack of financial information covering the period from October 1, 2019 through November 1, 2019, the Company was not able to provide pro forma adjusted financial statements for the nine months ended March 31, 2020 without making estimated extrapolations that the Company did not believe would be material or useful to users of the above pro forma information.
[4] Pro forma net loss per share calculations excluded the impact of the issuance of the (i) Series G Convertible Preferred Stock and the, (ii) Series H Convertible Preferred Stock under the assumption those shares would continue to remain non-participatory during the periods reported above.